To fill gaps in knowledge and management of pediatric obesity, a panel of healthcare professionals, caregivers, and people living with obesity, in partnership with Obesity Canada, collaborated on a clinical practice guideline for the management of pediatric obesity, published in CMAJ.
Advertisement
Joel Topf spoke to Excellence in Transplantation Award winner Jayme Locke at the National Kidney Foundation SCM25.
A study examined the effects of SGLT2i on eGFR slope in patients with autosomal dominant polycystic kidney disease.
Tonix Pharmaceuticals and Makana Therapeutics will collaborate on preclinical xenotransplantation research and development.
The FDA has granted Priority Review to pegcetacoplan to treat C3 glomerulopathy and primary IC-MPGN.
Researchers at SCM25 presented interim results of the SPARTAN trial of sparsentan as a treatment for patients with IgAN.
iDFS strongly correlates with OS in HR+/HER2- early breast cancer, supporting its use as a surrogate endpoint in trials.
Sacituzimab govitecan showed modest CNS activity in pretreated HER2-negative metastatic breast cancer with brain metastases.
Primary outcomes included new diagnosis of diabetes, cataracts, pneumonia, osteoporosis, or nontraumatic fractures.
DocWire Content Partners
Gain insights from The CardioNerds, a group of cardiology experts who aim to democratize cardiovascular education.
Fundamentals, core concepts, and important management approaches in the field of hematology and oncology
Dr. Chadi Nabhan, a renowned voice in hematology and oncology, tackles a multitude of relevant health care topics.
Drs. Rohit Gosain and Rahul Gosain discuss practice-changing data and standards of oncology care.
Dr. Hady Lichaa is an interventional cardiologist specializing in complex coronary interventions.
Review important issues in the rheumatology space, including lupus, rheumatoid arthritis, and more, from Dr. Maheswaranathan.
Powered by DocWire News
The Latest From GI Oncology Now
Suvemcitug, envafolimab, and FOLFIRI may serve as a new second-line treatment option for cold tumors.
KRASG12C inhibitors can have reduced efficacy in patients with alterations in KRAS, EGFR, and other genes.
Complete responders with HCC have prolonged survival and durable disease control even after therapy has been discontinued.
The primary objective of median PFS was significantly longer for patients treated with 177Lu-edotreotide.
The safety profile of the combination was consistent with known profiles, and no new safety findings were observed.
Older patients in their 70s with extrahepatic CCA have a higher rate of choledocholithiasis.
The Latest From Heme Today
In a phase 1 trial the product performed favorably in aplastic anemia, myelofibrosis, and hypoplastic myelodysplasia.
The reduced-dose oral regimen also had lower incidence of clinically relevant bleeding complications and mortality rate.
The platform features incubation technology able to replicate cell microenvironments associated with SCD sickling.
The FDA granted orphan drug designation to rilzabrutinib for warm autoimmune hemolytic anemia and IgG4-related disease.
ASH Awards Commitee Chair Ivan Maillard, MD, PhD, and prior awardee Rinku Majumder, PhD, tell of the Grant's positive impact.
Bexobrutideg, an orally bioavailable, brain-penetrant BTK degrader, is being evaluated in a phase 1a/b study.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.